The current study demonstrated that activation of c-Jun may have a protective role against sorafenib in the preliminary cell studies; nonetheless, a high expression level of p-c-Jun was associated with resistance to sorafenib and poor OS in patients with clinical HCC. Here, JUN is linked to hepatocellular carcinoma.